Literature DB >> 27943133

Targeting Functional Impairments in the Treatment of Children and Adolescents with ADHD.

Tyler Sasser1, Erin N Schoenfelder2, Mark A Stein2.   

Abstract

The diagnostic criteria for attention-deficit hyperactivity disorder (ADHD) require both symptoms and impairment to be present. Impairment in functioning is commonly the primary reason for referral, and is also a better predictor of long-term outcomes than ADHD symptoms. And yet, only recently has research begun to examine the impact of ADHD treatments on functional impairment using efficient and psychometrically sound outcome measures. In this article, we identify several noteworthy multidimensional measures of functional impairment (ADHD FX, Barkley Functional Impairment Scale [BFIS], Impairment Rating Scale [IRS], Weiss Functional Impairment Rating Scale [WFIRS]) utilized in recent clinical trials for ADHD, and describe their psychometric properties and clinical utility. We also review existing evidence on the impact of pharmacological and behavioral treatments on different domains of functional impairment in ADHD youth as measured by these specific measures. Further research is needed to evaluate longitudinal effects of ADHD treatments on functional impairment, and the use of these measures in adaptive treatment designs.

Entities:  

Mesh:

Year:  2017        PMID: 27943133     DOI: 10.1007/s40263-016-0400-1

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  57 in total

1.  Symptoms versus impairment: the case for respecting DSM-IV's Criterion D.

Authors:  Michael Gordon; Kevin Antshel; Stephen Faraone; Russell Barkley; Larry Lewandowski; James J Hudziak; Joseph Biederman; Charles Cunningham
Journal:  J Atten Disord       Date:  2006-02       Impact factor: 3.256

2.  Further measures of the psychometric properties of the Children's Global Assessment Scale.

Authors:  H R Bird; G Canino; M Rubio-Stipec; J C Ribera
Journal:  Arch Gen Psychiatry       Date:  1987-09

3.  Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.

Authors:  Amaia Hervas; Michael Huss; Mats Johnson; Fiona McNicholas; Judy van Stralen; Sasha Sreckovic; Andrew Lyne; Ralph Bloomfield; Vanja Sikirica; Brigitte Robertson
Journal:  Eur Neuropsychopharmacol       Date:  2014-10-23       Impact factor: 4.600

4.  Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment.

Authors:  R A Barkley; T L Shelton; C Crosswait; M Moorehouse; K Fletcher; S Barrett; L Jenkins; L Metevia
Journal:  J Child Psychol Psychiatry       Date:  2000-03       Impact factor: 8.982

5.  Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial.

Authors:  Raquel Vidal; Jordi Castells; Vanesa Richarte; Gloria Palomar; Marta García; Rosa Nicolau; Luisa Lazaro; Miguel Casas; Josep Antoni Ramos-Quiroga
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-01-26       Impact factor: 8.829

Review 6.  Peer functioning in children with ADHD.

Authors:  Betsy Hoza
Journal:  Ambul Pediatr       Date:  2007 Jan-Feb

7.  Use of the Child and Adolescent Functional Assessment Scale (CAFAS) as an outcome measure in clinical settings.

Authors:  K Hodges; M M Wong; M Latessa
Journal:  J Behav Health Serv Res       Date:  1998-08       Impact factor: 1.505

8.  Evaluation of a school-based treatment program for young adolescents with ADHD.

Authors:  Steven W Evans; Joshua M Langberg; Brandon K Schultz; Aaron Vaughn; Mekibib Altaye; Stephen A Marshall; Allison K Zoromski
Journal:  J Consult Clin Psychol       Date:  2015-10-26

9.  Assessing Impairment in Childhood ADHD: Validation of the Parent and Teacher ADHD-FX Rating Scale in a Dual-Site Clinical Sample.

Authors:  Lauren Marie Haack; Kelsey Gonring; Michael Harris; Alyson Gerdes; Linda Pfiffner
Journal:  J Atten Disord       Date:  2016-07-18       Impact factor: 3.196

10.  Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.

Authors:  Peter Nagy; Alexander Häge; David R Coghill; Beatriz Caballero; Ben Adeyi; Colleen S Anderson; Vanja Sikirica; Esther Cardo
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-05-22       Impact factor: 4.785

View more
  10 in total

1.  Refining treatment choices for ADHD.

Authors:  Anne Arnett; Mark Stein
Journal:  Lancet Psychiatry       Date:  2018-08-07       Impact factor: 27.083

2.  Culturally Appropriate Assessment of Functioning in Diverse Children: Development and Preliminary Validation of the FX-II Scale in Mexico.

Authors:  Lauren M Haack; Eva A Araujo
Journal:  J Atten Disord       Date:  2017-09-20       Impact factor: 3.256

3.  Psychometric properties of a modified version of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) in a clinical sample of children with aggressive behavior.

Authors:  Teresa Kernder; Manfred Doepfner; Christina Dose; Anja Goertz-Dorten
Journal:  Qual Life Res       Date:  2018-10-01       Impact factor: 4.147

4.  Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Steven R Pliszka; Timothy E Wilens; Samantha Bostrom; Valerie K Arnold; Andrea Marraffino; Andrew J Cutler; Frank A López; Norberto J DeSousa; Floyd R Sallee; Bev Incledon; Jeffrey H Newcorn
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-21       Impact factor: 2.576

5.  Conceptual review of measuring functional impairment: findings from the Weiss Functional Impairment Rating Scale.

Authors:  Margaret D Weiss; Nicole Michelle McBride; Stephanie Craig; Peter Jensen
Journal:  Evid Based Ment Health       Date:  2018-10-12

6.  A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.

Authors:  Ann C Childress; Andrew J Cutler; Andrea Marraffino; Mary Ann McDonnell; John M Turnbow; Matthew Brams; Norberto J DeSousa; Bev Incledon; Floyd R Sallee; Sharon B Wigal
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-08-29       Impact factor: 2.576

7.  Comorbidities and functional impairments in children with attention deficit hyperactivity disorder in China: a hospital-based retrospective cross-sectional study.

Authors:  Xiaoyan Shi; Yiting Ji; Shizhong Cai; Ying Wu; Lijun Zhang; Ling Shen; Zhiying Jiang; Yan Chen
Journal:  BMJ Open       Date:  2021-03-22       Impact factor: 2.692

8.  Associated predictors of functional impairment among adolescents with ADHD-a cross-sectional study.

Authors:  Jenny Meyer; Iman Alaie; Mia Ramklint; Johan Isaksson
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2022-04-05       Impact factor: 3.033

9.  A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder.

Authors:  Margaret Danielle Weiss
Journal:  Brain Sci       Date:  2022-07-31

10.  Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate.

Authors:  Timothy E Wilens; Stephen V Faraone; Paul G Hammerness; Steven R Pliszka; Cassandra L Uchida; Norberto J DeSousa; Floyd R Sallee; Bev Incledon; Jeffrey H Newcorn
Journal:  J Atten Disord       Date:  2021-06-04       Impact factor: 3.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.